中华医学杂志（英文版）2023，Vol.136Issue(22)：2677-2685,9.DOI:10.1097/CM9.0000000000002907
Efficacy and safety profiles of dolutegravir plus lamivudine vs.bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1
Efficacy and safety profiles of dolutegravir plus lamivudine vs.bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1
Yinghua Wei 1Jin Li 2Ruhong Xu 2Li Wen 3Yiming Deng 1Lixia He 1Huijun Zhong 2Yanhao Wang2
作者信息
- 1. Department of Infectious Diseases,The First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi 530021,China
- 2. Department of Infectious Diseases,The Ninth People's Hospital of Dongguan,Dongguan,Guangdong 523000,China
- 3. Center for Disease Control and Prevention of Jiulongpo District,Chongqing 400050,China
- 折叠
摘要
关键词
HIV-1/Antiretroviral therapy/Dolutegravir/Bictegravir/Efficacy/Safety/Target not detectedKey words
HIV-1/Antiretroviral therapy/Dolutegravir/Bictegravir/Efficacy/Safety/Target not detected引用本文复制引用
Yinghua Wei,Jin Li,Ruhong Xu,Li Wen,Yiming Deng,Lixia He,Huijun Zhong,Yanhao Wang..Efficacy and safety profiles of dolutegravir plus lamivudine vs.bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1[J].中华医学杂志（英文版）,2023,136(22):2677-2685,9.
